Search research articles
Contact Us
Filters
Showing results (51-60 of 62) with videos related to
Page
of 7
Sort By:
The Journal of Clinical Investigation
|
November 20, 1998
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
M A Winters, K L Coolley, Y A Girard, et al.
The New England Journal of Medicine
|
April 22, 1993
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection
P M Small, R W Shafer, P C Hopewell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
July 27, 2001
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy
N S Shulman, R A Machekano, R W Shafer, et al.
AIDS (London, England)
|
June 21, 2001
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy
N Shulman, A R Zolopa, D Passaro, et al.
Journal of Clinical Microbiology
|
April 3, 2001
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients
R W Shafer, K Hertogs, A R Zolopa, et al.
Antimicrobial Agents and Chemotherapy
|
February 19, 2000
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
L M Demeter, R W Shafer, P M Meehan, et al.
The Pharmacogenomics Journal
|
August 9, 2007
The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy
J A Canter, D W Haas, A R Kallianpur, et al.
The Journal of Infectious Diseases
|
April 1, 1994
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations
R W Shafer, M J Kozal, M A Winters, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 6, 2000
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response
N S Shulman, A R Zolopa, D J Passaro, et al.
Journal of Clinical Microbiology
|
July 1, 1996
Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group
R W Shafer, M A Winters, D L Mayers, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 62) with videos related to
Sort By:
Page
of 7
The Journal of Clinical Investigation
|
November 20, 1998
A 6-basepair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors
M A Winters, K L Coolley, Y A Girard, et al.
The New England Journal of Medicine
|
April 22, 1993
Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection
P M Small, R W Shafer, P C Hopewell, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
July 27, 2001
Genotypic correlates of a virologic response to stavudine after zidovudine monotherapy
N S Shulman, R A Machekano, R W Shafer, et al.
AIDS (London, England)
|
June 21, 2001
Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy
N Shulman, A R Zolopa, D Passaro, et al.
Journal of Clinical Microbiology
|
April 3, 2001
High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients
R W Shafer, K Hertogs, A R Zolopa, et al.
Antimicrobial Agents and Chemotherapy
|
February 19, 2000
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260)
L M Demeter, R W Shafer, P M Meehan, et al.
The Pharmacogenomics Journal
|
August 9, 2007
The mitochondrial pharmacogenomics of haplogroup T: MTND2*LHON4917G and antiretroviral therapy-associated peripheral neuropathy
J A Canter, D W Haas, A R Kallianpur, et al.
The Journal of Infectious Diseases
|
April 1, 1994
Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations
R W Shafer, M J Kozal, M A Winters, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)
|
June 6, 2000
Efavirenz- and adefovir dipivoxil-based salvage therapy in highly treatment-experienced patients: clinical and genotypic predictors of virologic response
N S Shulman, A R Zolopa, D J Passaro, et al.
Journal of Clinical Microbiology
|
July 1, 1996
Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group
R W Shafer, M A Winters, D L Mayers, et al.
Page
of 7